Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 inflammation.
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...
New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are ...
Malaysia has a new national plan to tackle cancer, tuberculosis, and chronic respiratory conditions in a single approach. Jacqui Thornton reports.
New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster ...
Studies have demonstrated a critical role of the cytokines thymic stromal lymphopoietin (TSLP), IL-33, and IL-25, produced by epithelial and other cells at mucosal surfaces in response to a wide range ...
Medical Device Network on MSN
Synchrony Medical bolsters US COPD treatment commercialisation with $5m funding round
Synchrony Medical's LibAirty system for addressing mucus obstruction in COPD patients gained FDA clearance in July 2025.
In an observational study that began enrollment last month, researchers will determine if continuous, remote lung sound ...
Inhaled maintenance therapy is underused among hospitalized patients with COPD in China, even in those with frequent prior hospitalizations.
Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results